EUCTR2015-002385-23-GB进行中（未招募）1 期
A phase 3 randomised, double blind, multiple dose, parallel group efficacy study of different doses of phenylephrine hydrochloride combined with paracetamol and/or ibuprofen in participants with nasal congestion associated with the common cold.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 275
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Male and/or female = 18 years of age
- •2)Presents cold symptoms which began within 96 hours of the study entry
- •3)Has a minimum score of 2 from the list of the following URTI symptoms: runny nose, blocked nose, sore throat and cough
- •4)For females – must be sterile or using adequate contraception
- •5)Has a baseline NAR = 0.25 Pa/cm3/sec
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 275
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Use of any nasal decongestant (systemic or topical) within the last 12 hours
- •2)Previous participation in this clinical trial
- •3)Is a member or relative of the study site staff
- •4)Consumption of alcohol within the last 6 hours
- •5)Use of menthol containing products within the last 6 hours
- •6)Has taken paracetamol or ibuprofen within the last 6 hours
- •7)Has a known history of allergic reaction or clinically significant intolerance to acetaminophen, ibuprofen or phenylephrine hydrochloride
- •8)Has a baseline NAR < 0.25 Pa/cm3/sec
- •9)Has experienced any surgical complications or other issues that, in the opinion of the investigator, could compromise the safety of the subject if he or she continues into randomized treatment or could confound the results of the study.
- •10)Has any clinically significant unstable cardiac, respiratory, neurological, immunological, haematological, or renal disease or any other condition that, in the opinion of the investigator, could compromise the subject’s welfare, ability to communicate with the study staff, or otherwise contraindicate study participation.
- •11)Has a history or current diagnosis of a significant psychiatric disorder that, in the opinion of the investigator, would affect the subject’s ability to comply with the study requirements.
- •12)Has anatomical nasal obstruction or gross anatomical deformity, including moderately or severely deviated septum or the presence of nasal polyps.
- •13)Has a history of bacterial sinusitis diagnosed in the previous two weeks prior to participating in this trial.
- •14)Has any clinically significant finding at Screening that, in the opinion of the investigator, contraindicates study participation.
- •15)Previously participated in another clinical study within 30 days before Screening.
- •16)Has used antibiotics within 10 days prior to entry
- •17)Has used tricyclic antidepressants or monoamine oxidase inhibitors within the last 30 days
- •18)Cannot abstain from smoking during the whole duration of the trial
- •19)Females of childbearing potential not using adequate contraception. A woman of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a partial or total hysterectomy or surgical sterilisation.
- •20)Women that are lactating, or known to be pregnant or possibly pregnant
研究者
相似试验
进行中（未招募）
1 期
A study to determine the safety and the efficacy of fasinumab compared to placebo and naproxen for treatment of adults with pain from osteoarthritis of the knee or hipPain due to osteoarthritis of the knee or hipMedDRA version: 20.0Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859MedDRA version: 20.0Level: LLTClassification code 10020108Term: Hips osteoarthritisSystem Organ Class: 100000004859EUCTR2016-005020-29-ESRegeneron Pharmaceuticals, Inc.3,640
进行中（未招募）
1 期
A study to determine the safety and the efficacy of fasinumab compared to placebo and naproxen for treatment of adults with pain from osteoarthritis of the knee or hipEUCTR2016-005020-29-PLRegeneron Pharmaceuticals, Inc.2,845
进行中（未招募）
1 期
A study to determine the safety and the efficacy of fasinumab compared to placebo and naproxen for treatment of adults with pain from osteoarthritis of the knee or hipPain due to osteoarthritis of the knee or hipMedDRA version: 21.1Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859MedDRA version: 21.1Level: LLTClassification code 10020108Term: Hips osteoarthritisSystem Organ Class: 100000004859EUCTR2016-005020-29-BGRegeneron Pharmaceuticals, Inc.2,845
进行中（未招募）
1 期
A study to determine the safety and the efficacy of fasinumab compared to placebo and naproxen for treatment of adults with pain from osteoarthritis of the knee or hipEUCTR2016-005020-29-DKRegeneron Pharmaceuticals, Inc.2,845
进行中（未招募）
1 期
A study to determine the safety and the efficacy of fasinumab compared to placebo and naproxen for treatment of adults with pain from osteoarthritis of the knee or hipPain due to osteoarthritis of the knee or hipMedDRA version: 21.1Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859MedDRA version: 21.1Level: LLTClassification code 10020108Term: Hips osteoarthritisSystem Organ Class: 100000004859EUCTR2016-005020-29-LTRegeneron Pharmaceuticals, Inc.2,845